BioNTech Expands COVID-19 Vaccine Output Again, Forecasts $10bn Revenues

Also Increasing Oncology Trials

Success of the vaccine will fuel the company’s push into immunotherapy, as it reported first commercial sales.

Mainz, Rheinland-Pfalz, Germany-9. September 2020 Biontech building in Mainz with the sun shining and waving flags
BioNTech has been transformed into a European biotech powerhouse, with a market cap of $26bn and vaccines revenues to fund its ambitions in immunotherapy.

BioNTech and Pfizer are set to increase production of their COVID-19 vaccine Comirnaty to 2.5 billion doses by the end of 2021, just as they look to expand into new geographies and younger age groups.

This is thanks in part to BioNTech’s new facility in Marburg, Germany, coming on stream, helping to lift the partners’...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip